AE Management for CAR-T Therapy: Expert Insights and Perspectives
Samer Al'Hadidi, MD, provides a comprehensive overview of adverse event management practices for patients with multiple myeloma who receive CAR T-cell therapy.
EP: 1.Advancements in the Treatment of Newly Diagnosed MM: Updates from the Phase 3 IMROZ Study
EP: 2.Navigating Treatment Advancements and Recent Approvals in R/R Multiple Myeloma: Expert Insights
EP: 3.Updates From the Phase 2 MonumenTAL-2 Study Investigating Talquetamab in R/R MM
EP: 4.Long-Term Follow-up with Teclistamab in R/R MM: Updates from MajesTEC-1
EP: 5.Treatment Strategies with Elranatamab in R/R MM: Updates from the MagnetisMM Trials
EP: 6.Expert Perspectives: Sequencing Approaches with CAR-T and Bispecifics in R/R MM
EP: 7.Expert Insights: Strategies for Step-Up Dosing and Long-Term Treatment Management with Bispecifics in R/R MM
EP: 8.The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS
EP: 9.Considerations in Sequencing BCMA-Targeting Bispecifics and CAR-T Therapies in R/R MM
EP: 10.Cilta-cel in R/R MM: ASCO 2024 Updates from CARTITUDE Trials
Now Viewing
EP: 11.AE Management for CAR-T Therapy: Expert Insights and Perspectives
EP: 12.Looking Ahead: ASCO 2024 Updates and Future Perspectives
EP: 13.Key Takeaways and Clinical Pearls on the Treatment of R/R MM in the Era of Bispecifics
EP: 14.Bispecific Antibodies Are Taking the Multiple Myeloma World by Storm
Video content above is prompted by the following questions:
- Please discuss AE management practices for CAR T-cell therapy.
- What are some adverse events seen with ide-cel and cilta-cel?
- Review some strategies to help manage AEs.
- How do they compare with bispecifics?
Recent Videos
Related Content
